COMPASS Pathways Completes NDA Submission for COMP360 Psilocybin

COMPASS Pathways completed its New Drug Application submission to the FDA for COMP360, its proprietary synthetic psilocybin therapy for treatment-resistant depression. The company is targeting a commercial launch in the first half of 2027, subject to regulatory approval and DEA rescheduling.